ライフサイエンスコーパス: Toll-like receptor 9

1 ted to be a novel proinflammatory ligand for Toll-like receptor 9.

2 ly endocytic compartments in pDCs to trigger Toll-like receptor 9.

3 ferently directed to the B-cell receptor and Toll-like receptor 9.

4 recognition threshold for the activation of Toll-like receptor 9.

5 ction and organ damage through activation of Toll-like receptor 9.

6 s modified by the expression of its receptor toll-like receptor-9.

7 t was achieved, in part, by IFN-1 induced by Toll-like receptor 9-activated cDCs.

8 ort isoform predominates in CD27(+) B cells, toll-like receptor 9-activated peripheral B cells, and s

9 outcome of severe sepsis is associated with toll-like receptor 9 activation in neutrophils, which tr

10 e bone marrow both in vitro and in vivo upon Toll-like receptor-9 activation and whose adoptive trans

11 Via Toll-like receptor 9 agonism of dendritic cells and B ce

12 Toll-like receptor-9 agonism with CYT003 showed no addit

13 treatment with antigen in the presence of a Toll-like receptor 9 agonist can suppress TH2-mediated r

14 particle with CpG-motif G10 inside), a novel Toll-like receptor 9 agonist packaged into virus-like pa

15 A (siRNA) delivery platform by conjugating a Toll-like receptor 9 agonist with siRNA that efficiently

16 ed the IgG response by coadministration of a Toll-like receptor 9 agonist, among other adjuvants exam

17 wed that stimulation of innate immunity with Toll-like receptor 9 agonist, class B CpG (cytosine-phos

18 missible gastroenteritis virus (TGEV) or the Toll-like receptor 9 agonist, oligodeoxynucleotide (ODN)

19 f CpG oligodeoxynucleotide 2216 (ODN2216), a Toll-like receptor 9 agonist, was investigated with mono

20 s formulated with the adjuvant PF03512676, a Toll-like receptor 9 agonist, which augments cellular im

21 hout co-administration or encapsulation of a Toll-Like Receptor 9 agonist.

22 We found that in response to the Toll-like receptor-9 agonist CpGA, plasmacytoid dendriti

23 In a Phase 2a trial, CYT003, a Toll-like receptor-9 agonist immunomodulator, improved a

24 We tested whether Toll-like receptor 9 agonists increased TACI expression

25 otein formulated in Toll-like receptor 7 and Toll-like receptor 9 agonists, and DNA priming followed

26 naive B cells via B-cell receptor (BCR) and Toll-like receptor 9, along with T-cell help, failed to

27 Breg cells obtained by Toll-like receptor 9 and CD40 activation of B cells prev

28 naling influences the liver DC expression of toll-like receptor 9 and IL-1 receptor associated kinase

29 s for innate antiviral responses, triggering Toll-like receptor 9 and inducing alpha/beta interferon

30 Macrophage activation by CpG DNA requires toll-like receptor 9 and the adaptor protein MyD88.

31 id dendritic cells, leading to activation of Toll-like receptor-9 and induction of type I IFNs.

32 ral killer cell dependent and ineffective in Toll-like Receptor 9(-/-) and interleukin 6(-/-) mice, w

33 as partially CD4 dependent and functional in Toll-like Receptor 9(-/-) and interleukin 6(-/-) mice.

34 bacteria, T-cell-independent activation via Toll-like receptor 9, and differentiation into non-NTHi-

35 , Henault et al. show that Fcgamma-receptor, Toll-like receptor 9, and LC3 conspire to mold phagosome

36 phosphate-guanosine (CpG) DNA motifs through toll-like receptor 9, and we found that the synthetic Cp

37 somal acidification inhibitor chloroquine, a Toll-like receptor 9 antagonist inhibitory CpG DNA, or o

38 asmacytoid dendritic cells via activation of Toll-like receptor 9, but independently of the IL-26 rec

39 Upon investigating the mechanism by which toll-like receptor 9 deficiency prevents the failure of

40 Toll-like receptor 9-deficient mice with cecal ligation

41 cecal ligation and puncture in wild-type and toll-like receptor 9-deficient mice.

42 , it was found that neutrophils derived from toll-like receptor 9--deficient mice with cecal ligation

43 Neutrophil Toll-like receptor 9 expression correlated with plasma i

44 These data point to neutrophil Toll-like receptor 9 expression in acetaminophen-induced

45 Healthy neutrophil Toll-like receptor 9 expression increased upon stimulati

46 Circulating neutrophil Toll-like receptor 9 expression was increased in acetami

47 e score (2-4) on day 1 had higher neutrophil Toll-like receptor 9 expression, arterial ammonia concen

48 sociated with mortality in patients with low toll-like receptor-9 expression (odds ratio, 1.1; p = 0.

49 Stratification of patients according to toll-like receptor-9 expression above/below median demon

50 Toll-like receptor-9 expression in monocytes was measure

51 particular present in patients with elevated toll-like receptor-9 expression.

52 e liver failure plasma and endogenous DNA on Toll-like receptors-9 expression, healthy neutrophils we

53 he toll-like receptor 4 gene (TLR4), and the toll-like receptor 9 gene (TLR9) in a cohort of 336 reci

54 Unexpectedly, loss of the Toll-like receptor 9 has a minimal effect on Akt activat

55 cognize CpG DNA express membrane-bound human Toll-like receptor 9 (hTLR9).

56 -kappaB-->ZEB1 signaling represses the TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattrac

57 Colocalization of CpG DNA with Toll-like receptor 9 in endosomal vesicles is disrupted

58 Toll-like receptor 9 with a telomere-derived Toll-like receptor 9 inhibitory oligonucleotide or trans

59 Our study identifies Toll-like receptor 9 inhibitory oligonucleotides as pote

60 or 9 inhibitory oligonucleotide or transient Toll-like receptor 9 knockdown with small interfering RN

61 and defective responses to stimulation with Toll-like receptor 9 ligand (TLR9-L), regardless of the

62 our previous finding that the combination of Toll-like receptor 9 ligand CpG and interleukin (IL)-4 s

63 or to treatment with poly-ICLC or a specific Toll-like receptor 9 ligand, CpG oligodeoxynucleotides.

64 toll-like receptor-9 ligand, CpG DNA, enhanced luciferas

65 or prostate cancer cells stably adorned with Toll-like receptor-9 ligand-loaded particles using strep

66 tion of IL-8 was observed using conventional Toll-like receptor 9 ligands (CpG oligonucleotides), alt

67 After Toll-like receptor-9 ligation, expanded liver pDCs secre

68 adation after pressure overload can activate Toll-like receptor-9 mediated innate immunity, causing m

69 in CLL by suppressing BCR, CD49d, CD40, and Toll-like receptor 9-mediated AKT activation in an integ

70 In contrast to the Toll-like receptor 9-mediated recognition observed in pl

71 pite functionally intact IL-21 receptor- and Toll-like receptor 9-mediated signal transducer and acti

72 CD40 ligand- and Toll-like receptor 9-mediated signaling were less strong

73 eatment inhibited Toll-like receptor 4, MD2, Toll-like receptor 9, myeloid differentiation factor 88,

74 fs mimic microbial DNA and are recognized by toll-like receptor 9 on immune cells.

75 at stimulate innate immune responses through Toll-like receptor-9 on B cells and plasmacytoid dendrit

76 vates the innate immune system by binding to toll-like receptor-9 on immune cells.

77 e in vitro stimulation of B-cell receptor or Toll-like receptor 9 pathways were reduced in patients w

78 Lung ST2L and toll-like receptor 9 protein expression levels concomita

79 Toll-like receptor 9 recognizes CpG DNA and elicits inna

80 dings demonstrate that bacterial DNA through Toll-like receptor 9 shifted the balance of tissue facto

81 d that only patients with high expression of toll-like receptor-9 showed an increased risk associated

82 e reversed by activation of APCs via CD40 or Toll-like receptor 9 signaling.

83 l and that TRAF6 is a diverging point in the Toll-like receptor 9-signaling pathway for CpG DNA-media

84 h it could be demonstrated that parts of the Toll-like receptor 9-signaling pathway were functional,

85 However, Toll-like receptor 9 stimulation alone significantly inc

86 recognition threshold for the activation of Toll-like receptor 9, the principal DNA-recognizing tran

87 cterial DNA enhance immune responses through Toll-like receptor 9 (TLR-9) and may also demonstrate ad

88 ion in human monocytic cells (THP-1) through Toll-like receptor 9 (TLR-9) and nuclear factor-kappaB s

89 oduction by human PDCs through engagement of Toll-like receptor 9 (TLR-9) and TLR-7, respectively, wi

90 The Toll-like receptor 9 (TLR-9) gene has recently emerged a

91 rich in unmethylated CG motifs (CpGs) engage Toll-Like Receptor 9 (TLR-9) in endosomes and are well d

92 er cells after vaccination with antigen plus Toll-like receptor 9 (TLR-9) ligand.

93 pression of bacterial DNA sensors, including Toll-like receptor 9 (TLR-9), DNA-dependent activator of

94 d CpG-containing DNA, which is recognized by Toll-like receptor 9 (TLR-9), has been strongly implicat

95 ization to early endosomes and signaling via Toll-like receptor 9 (TLR-9), it can result in product p

96 flammatory contributors to a murine model of Toll-like receptor 9 (TLR-9)-induced fulminant MAS.

97 , and the capacity to respond to ligands for Toll-like receptor 9 (TLR-9; CpG ODN 1668), but not to l

98 focuses on sublingual immunotherapy (SLIT), toll-like receptor-9 (TLR-9) vaccines using cytosine pho

99 To determine whether mast cells express Toll-like receptor-9 (TLR-9; the receptor for ISS), TLR-

100 ich was prevented by CXCR2-FPR1 blockage and Toll-like receptor 9 (TLR9) absence (TLR9(-/-) mice).

101 ication (FLT3-ITD)-negative AML, BTK couples Toll-like receptor 9 (TLR9) activation to nuclear factor

102 re cultured with CD40 ligand (CD40L) and the Toll-like receptor 9 (TLR9) agonist cytidine-phosphate-g

103 Previous clinical studies suggest that the Toll-Like Receptor 9 (TLR9) agonist DIMS0150 not only in

104 lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic ant

105 a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and i

106 uanidine (CpG) oligodeoxynucleotide (ODN), a toll-like receptor 9 (TLR9) agonist, confers protection

107 thesized that a single drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could funct

108 dulates the type I IFN response of IPCs to a Toll-like receptor 9 (TLR9) agonist.

109 Toll-like receptor 9 (TLR9) agonists such as unmethylate

110 his study we observed that administration of Toll-like receptor 9 (TLR9) agonists suppressed the seve

111 lymphocyte-associated antigen 4 (CTLA4) and toll-like receptor 9 (TLR9) agonists.

112 ly, we identify parasite DNA-sensing through Toll-like receptor 9 (TLR9) along with inflammatory cyto

113 Unmethylated CpG DNA binds to the Toll-like receptor 9 (TLR9) and activates NF-kappaB to i

114 okines via a cooperative interaction between Toll-like receptor 9 (TLR9) and FcgammaRIIa (CD32).

115 Toll-like receptor 9 (TLR9) and NLRP3 inflammasome were

116 nition of adenovirus by pDCs was mediated by Toll-like receptor 9 (TLR9) and was dependent on MyD88,

117 70S6K1 and p70S6K2, during pDC activation by Toll-like receptor 9 (TLR9) blocked the interaction of T

118 Stimulation of Toll-like receptor 9 (TLR9) by DNA is important in the a

119 major role in intestinal homeostasis through Toll-like receptor 9 (TLR9) engagement.

120 Toll-like receptor 9 (TLR9) enhances proinflammatory res

121 The activation of Toll-like receptor 9 (TLR9) expressed within B cells is

122 clude the BMAL1:CLOCK heterodimer regulating toll-like receptor 9 (TLR9) expression and repressing ex

123 Although Toll-like receptor 9 (TLR9) has been implicated in cytok

124 l early in clinical development, agonists of Toll-like receptor 9 (TLR9) have demonstrated potential

125 The role of Toll-like receptor 9 (TLR9) in antifungal responses in t

126 engagement of the B cell receptor (BCR) and Toll-like receptor 9 (TLR9) in response to DNA-containin

127 -mobility group B1 (HMGB1) protein activates Toll-like receptor 9 (TLR9) in the adipose-recruited pDC

128 a key role in recognition, as highlighted by Toll-like receptor 9 (TLR9) in the endosomal compartment

129 Toll-like receptor 9 (TLR9) is a pattern recognition rec

130 The Toll-like receptor 9 (TLR9) is activated by DNA presente

131 Toll-like receptor 9 (TLR9) is an endosome bound, innate

132 At present, Toll-like receptor 9 (TLR9) is thought to play a central

133 that following challenge with A. fumigatus, Toll-like receptor 9 (TLR9) knockout mice survived longe

134 We investigated the ability of the Toll-like receptor 9 (TLR9) ligand CpG to modulate estab

135 raft-versus-host disease (GVHD) lethality by Toll-like receptor 9 (TLR9) ligation of host antigen-pre

136 CLL cells selectively express high levels of Toll-like receptor 9 (TLR9) mRNA and proteins.

137 A role for Toll-like receptor 9 (TLR9) recognition of Ad was suppor

138 Toll-like receptor 9 (TLR9) recognizes genomes of double

139 Toll-like receptor 9 (TLR9) recognizes microbial DNA in

140 Toll-like receptor 9 (TLR9) recognizes unmethylated CpG

141 Toll-like receptor 9 (TLR9) senses microbial DNA and tri

142 d-induced IL-1beta release is dependent upon Toll-like receptor 9 (TLR9) sensing of the Ad5 double-st

143 endent on an autophagy and mitochondrial DNA/Toll-like receptor 9 (TLR9) signaling pathway.

144 ke into endosomes, the rate-limiting step of Toll-like receptor 9 (TLR9) signaling, is critical in el

145 to IgM-secreting plasma cells in response to Toll-like receptor 9 (TLR9) signaling.

146 responsiveness of paired lung fibroblasts to Toll-like receptor 9 (TLR9) stimulation by CpG-oligodeox

147 ning oligodeoxynucleotides (CpG ODNs) act on Toll-like receptor 9 (TLR9) that is expressed on B cells

148 induction of NK-cell activity in response to Toll-like receptor 9 (TLR9) triggering.

149 tion and immunoglobulin production driven by Toll-like receptor 9 (TLR9) were considerably lower in D

150 stimulated the innate immune system via the Toll-like receptor 9 (TLR9) with cytosine-guanosine-cont

151 act with ACs, results from the engagement of Toll-like receptor 9 (TLR9) within the B cell after reco

152 Toll-like receptor 9 (TLR9), a member of the interleukin

153 Toll-like receptor 9 (TLR9), a receptor for CpG DNA, has

154 ear factor-kappaB transcription factor RelB, toll-like receptor 9 (TLR9), and interferon consensus se

155 robial DNA to its cognate receptors, such as Toll-like receptor 9 (TLR9), can trigger inflammation.

156 hed oligodeoxynucleotide, an agonist for the toll-like receptor 9 (TLR9), induces the activation of n

157 Toll-like receptor 9 (TLR9), its adaptor MyD88, the down

158 recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor

159 tic DNA rich in CpG dinucleotides stimulates Toll-like receptor 9 (TLR9), whereas DNA lacking CpG eit

160 pDCs sense viral DNA via Toll-like receptor 9 (TLR9), which has to be cleaved fro

161 ell-receptor signaling induces the fusion of Toll-like receptor 9 (TLR9)-containing endosomes with in

162 Toll-like receptor 9 (TLR9)-deficient (TLR9(-/-)) mice a

163 ow that Opn deficiency substantially reduced Toll-like receptor 9 (TLR9)-dependent IFN-alpha response

164 Here, we report a novel Toll-like receptor 9 (TLR9)-dependent mechanism that ini

165 e and antibody production by B cells via the Toll-like receptor 9 (TLR9)-dependent pathway.

166 FcvarepsilonRI receptor for IgE, followed by Toll-like receptor 9 (TLR9)-mediated sensing of DNA in p

167 intravenous DNASE1 injection or ablation of Toll-like receptor 9 (TLR9)-mediated sensing significant

168 227A signaling and B-cell receptor (BCR)- or Toll-like receptor 9 (TLR9)-mediated signaling was also

169 In this study, we report that the Toll-like receptor 9 (TLR9)-MyD88 pattern-recognition re

170 trategy based on targeted Stat3 silencing in Toll-like receptor 9 (TLR9)-positive hematopoietic cells

171 a defective response to ligation of BCR and Toll-like receptor 9 (TLR9).

172 activates the innate immune response through Toll-like receptor 9 (TLR9).

173 ng unmethylated CpG motifs act as ligands of Toll-like receptor 9 (TLR9).

174 oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9).

175 containing unmethylated CpG motifs activate Toll-like receptor 9 (TLR9).

176 og CpG-ODN activates innate immunity through Toll-like receptor 9 (TLR9).

177 cells is known to activate immune cells via Toll-like receptor 9 (TLR9).

178 immune responses generated through MyD88 and Toll-like receptor 9 (TLR9).

179 containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9).

180 taining oligodeoxynucleotides that stimulate toll-like receptor 9 (TLR9).

181 ning unmethylated CpG dinucleotides activate Toll-like receptor 9 (TLR9).

182 nflammatory response, presumably mediated by Toll-like receptor 9 (TLR9).

183 ctivate the vertebrate immune system through Toll-like receptor 9 (TLR9).

184 engagement of the B cell receptor (BCR) and Toll-like receptor 9 (TLR9).

185 ession of the pathogen recognition receptor, Toll-like receptor 9 (TLR9).

186 pG-ODN), the microbial DNA mimetic sensed by toll-like receptor 9 (TLR9).

187 lock controls the expression and function of Toll-like receptor 9 (TLR9).

188 s type 1 (HSV-1) in vitro is mediated by the toll-like receptor 9 (TLR9)/MyD88 pathway.

189 Toll-like receptor-9 (TLR9) has been shown to sense bact

190 Toll-like receptor-9 (TLR9) is largely responsible for d

191 r advanced glycation end products (RAGE) and Toll-like receptor-9 (TLR9).

192 ndritic cells (pDCs) by binding to endosomal Toll-like receptor-9 (TLR9; refs 1-5).

193 Although Toll-like receptor 9 triggering normally up-regulates B-

194 stem and microglia/macrophage activation via Toll-like receptor 9 using CpG (cytosine-phosphate-guani

195 Intracellular Toll-like receptor 9 was induced by costimulation with i

196 th CRS, although a 50% reduced expression of Toll-like receptor 9 was reported in patients with recal

197 Inhibition of Toll-like receptor 9 with a telomere-derived Toll-like r

198 -containing oligodeoxynucleotides binding to toll-like receptor 9, with enhanced IFN-alpha transcript